Breast cancer treatment time could be HALVED

British research from the University of Warwick and the University of Cambridge has revealed the amount of time a person needs on herceptin could be halved from 12 months to six (stock).
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

CONCLUSIONS: Oncotype is a cost-effective intervention from a health system perspective since each QALY gained costs less than 25,000 euros. From a societal perspective, it is dominant since it provides greater health and is accompanied by cost savings. PMID: 30442434 [PubMed - as supplied by publisher]
Source: Gaceta Sanitaria - Category: International Medicine & Public Health Tags: Gac Sanit Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: Opinion Source Type: research
AbstractPurpose of ReviewSeveral multigene assays have been developed to guide adjuvant therapy decisions for early-stage invasive breast cancer, including the 21-gene recurrence score, 70-gene assay, EndoPredict, PAM50 Risk of Recurrence, and Breast Cancer Index.Recent FindingsEach assay has varying levels of evidence to support the analytical validity, clinical validity, and clinical utility in providing prognostic information complementary to conventional clinical characteristics. While each test is able to identify patients at low risk of distant recurrence, understanding the differences in development and studies used...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
CONCLUSIONS The findings of this study support a role for c-Met as a clinical prognostic marker and for c-Met and TOPO II as predictive markers for response to chemotherapy in patients with breast cancer. PMID: 30444219 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
The sensitivity of MDA-MB231 breast cancer cells to the effects of pharmacological agents was evaluated by their motility and viability. Dexamethasone, doxorubicin, or docetaxel administered separately in their effective concentration suppressed cell motility (in 16 h) and caused cell death (in 48 h). The strength of the effects increased in the following order: dexa methasone
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research
We studied myelotoxicity of modern schemes of chemotherapy for breast cancer (docetaxel/doxorubicin and cyclophosphamide/doxorubicin/5-fluorouracil) towards granulocytopoiesis, the mechanisms determining the differences of hematological effects of these schemes, and the efficiency of correction of the observed changes with granulocyte CSF (filgrastim). Granulocytopoiesis stimulation with filgrastim during the treatment with docetaxel/doxorubicin combination was more pronounced than during cyclophosphamide/doxorubicin/5-fluorouracil therapy. The observed differences were found at all levels of granulocyte lineage organizati...
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research
Publication date: Available online 17 November 2018Source: Pathology - Research and PracticeAuthor(s): Li MaAbstractNeoadjuvant chemotherapy(NCT) has become the standard treatment for breast cancer. The information about the tumor’s sensitivity to chemotherapy and prognostic significance based on response to therapy can be provided after individualized neoadjuvant treatment. The biomarkers are key factors in the decision-making process regarding treatment as well as important prognostic indicators. Studies have shown that patients who achieve pathological complete response(pCR) after NCT have a better prognosis. For ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 17 November 2018Source: International Journal of PharmaceuticsAuthor(s): Nicolò Mauro, Cinzia Scialabba, Roberto Puleio, Paola Varvarà, Mariano Licciardi, Gennara Cavallaro, Gaetano GiammonaAbstractThe extremely complex tumor microenvironment (TME) in humans is the major responsible for the therapeutic failure in cancer nanomedicine. A new concept of disease-driven nanomedicine, henceforth named “Theranomics”, which attempts to target cancer cells and TME on the whole, represents an attractive alternative. Herein, a nanomedicine able to co-deliver doxorubicin and...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 16 November 2018Source: Seminars in Cell &Developmental BiologyAuthor(s): Choon Leng So, Jodi M. Saunus, Sarah J. Roberts-Thomson, Gregory R. MonteithAbstractThe past two decades have seen the identification of important roles for calcium signalling in many of the hallmarks of cancer. One of the cancer types that has been a particular focus of such studies is breast cancer. The breast is intrinsically linked to the calcium ion due to the importance of milk calcium in neonatal growth and development. Indeed, some of the calcium channels and pumps involved in transporting calcium ions i...
Source: Seminars in Cell and Developmental Biology - Category: Cytology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Herceptin | UK Health